Ulrike Gnad-Vogt
Corporate Officer/Principal bij CUREVAC N.V.
Vermogen: 103 438 $ op 31-03-2024
Profiel
Ulrike Gnad-Vogt is currently working as the Chief Medical Officer at CureVac SE since 2011.
Additionally, she holds the position of Senior Vice President & Head-Oncology at CureVac NV since 2011.
Dr. Gnad-Vogt obtained a doctorate degree from Universität des Saarlandes.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CUREVAC N.V.
0.02% | 31-03-2023 | 34 138 ( 0.02% ) | 103 438 $ | 31-03-2024 |
Actieve functies van Ulrike Gnad-Vogt
| Bedrijven | Functie | Begin |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 01-01-2019 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01-01-2011 |
Opleiding van Ulrike Gnad-Vogt
| Universität des Saarlandes | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
